17 research outputs found

    MOESM1 of Effects of pretreatment with methanol extract of Peucedani Radix on transient ischemic brain injury in mice

    No full text
    Additional file 1: Figure S1. High performance thin layer chromatography (HPTLC) images of methanol extract of Peucedani Radix (PRex) fingerprinting. Figure S2. Schematic view of neuro-protective mechanisms of PRex in MCAO mice model

    Additional file 1: Table S1. of The association between physical activity and health-related quality of life among breast cancer survivors

    Get PDF
    Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors by body mass index. Table S2. Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors by menopausal status at the diagnosis. Table S3. Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors by time since surgery. Table S4. Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors by age at diagnosis. (DOCX 48 kb

    The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients

    No full text
    <div><p>Purpose</p><p>This study evaluated the association of serum HER2 (sHER2) levels at diagnosis with clinicopathologic parameters and disease free survival (DFS) in operable breast cancer patients according to intrinsic subtype.</p><p>Methods</p><p>The sHER2 levels were measured using a chemiluminescence immunoassay. The HER2 status in all tumor tissues was determined by immunohistochemistry, and confirmed in equivocal cases by fluorescence in situ.</p><p>Results</p><p>There were 436 consecutive stage I-III breast cancer patients with sHER2 result at diagnosis between Nov 2004 and Dec 2011. High sHER2 levels (≥ 15 ng/ml) were reported in 52 patients (11.9%) and HER2 overexpression in tumor tissue was observed in 111 patients (25.5%). High sHER2 levels were associated significantly with advanced stage (<i>P</i> < 0.001), mastectomy (<i>P</i> = 0.012), neoadjuvant chemotherapy (<i>P</i> < 0.001), anti-HER2 therapy (<i>P</i> < 0.001) and hormone therapy (<i>P</i> = 0.022). The patients with high sHER2 levels had a worse DFS (<i>P</i> < 0.001). In multivariate analysis, high sHER2 levels were associated significantly with worse DFS (HR = 2.25, 95% CI 1.27–3.99, <i>P</i> = 0.005). High sHER2 levels were associated with worse DFS in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes (<i>P</i> = 0.043, 0.003 and 0.041, respectively).</p><p>Conclusions</p><p>These results show that the sHER2 level at diagnosis is a useful prognostic factor in patients with operable breast cancer, especially in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes.</p></div
    corecore